Sertraline Hydrochloride Tablet
Product Images NDC 43602-980

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Sertraline Hydrochloride (NDC 43602-980). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascent Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sertraline HCl Tablets-100 mg (100mg)

Label of Sertraline Hydrochloride Tablets USP, 100 mg strength, oral tablet form. The label indicates 500 tablets per container, is for pharmacist dispensing, and prescription use only. It is manufactured by Ascent Pharmaceuticals, Inc. Storage instructions and dosage referencing prescribing information are included.*

FDA Label Image

Sertraline HCl Tablets-25 mg (25mg)

Label for Sertraline Hydrochloride Tablets, USP 25 mg oral tablets by Ascent Pharmaceuticals, Inc. The package contains 500 tablets and is labeled for Rx only. The label includes the NDC 43602-979-16, storage instructions between 20°C to 25°C, and a note on pharmacist dispensing instructions and dosage guidance.*

FDA Label Image

Sertraline HCl Tablets-50 mg (50mg)

Label for Sertraline Hydrochloride Tablets USP 50 mg oral tablets by Ascent Pharmaceuticals, Inc. The label indicates 500 tablets per bottle, prescription only, and includes storage instructions, pharmacist dispensing guidance, and a barcode.*

FDA Label Image

Common Side Effects (Commonsideeffects)

A partial text panel listing potential adverse reactions including nausea, loss of appetite, diarrhea, indigestion, increased sweating, tremor or shaking, agitation, changes in sleep habits, sexual problems, fatigue, and anxiety. The content appears to be from a patient information leaflet or prescribing information for sertraline hydrochloride tablets.*

FDA Label Image

Health Problems (Healthproblems)

This text panel lists several medical conditions and health factors to consider, including liver problems, heart problems, bipolar disorder or mania, kidney problems, seizures or convulsions, low sodium blood levels, history of stroke, high blood pressure, and history of bleeding problems.*

FDA Label Image

Serious Symptoms (Serioussymptoms)

This image shows a partial text panel listing potential adverse reactions or symptoms such as high fever, rapid changes in heart rate or blood pressure, uncontrolled muscle spasms, confusion, stiff muscles, and loss of consciousness (passing out). The text appears to be part of a warning or side effects section related to SERTRALINE HYDROCHLORIDE tablets.*

FDA Label Image

Structure (Structure)

Chemical structure of sertraline hydrochloride, showing the molecule's key rings, chlorine atoms, and hydrochloride salt representation.*

FDA Label Image

Symptoms 1 (Symptoms 1)

A drug facts or safety warning panel listing behavioral and mood symptoms to watch for, such as suicide attempts, aggression, depression, agitation, increased activity, dangerous impulses, suicidal thoughts, anxiety or panic attacks, trouble sleeping, and other unusual changes in behavior or mood.*

FDA Label Image

Symptoms 2 (Symptoms 2)

A partial text panel listing possible symptoms such as agitation, hallucinations, coma, changes in mental status, racing heartbeat, blood pressure issues, coordination problems, muscle twitching, nausea, vomiting, diarrhea, sweating, fever, and muscle rigidity. The text is related to side effects or warnings, likely from medication safety information.*

FDA Label Image

Symptoms 4 (Symptoms 4)

The image shows a partial list of possible behavioral side effects related to sertraline hydrochloride, including symptoms such as greatly increased energy, racing thoughts, unusually grand ideas, severe trouble sleeping, reckless behavior, excessive happiness or irritability, and talking more or faster than usual.*

FDA Label Image

Symptoms 8 (Symptoms 8)

A partial text panel listing side effects associated with the drug, including headache, weakness or feeling unsteady, and confusion, problems concentrating or thinking, or memory problems. The text is presented in bulleted format on a white background.*

FDA Label Image

Table 1 (Table 1)

Data table showing recommended daily dosages of sertraline hydrochloride for adults and pediatric patients with conditions including MDD, OCD, PD, PTSD, and SAD. It lists starting doses and therapeutic ranges by indication and age group, with dosages ranging from 25 mg to 200 mg.*

FDA Label Image

Table 2 (Table 2)

A data table presenting risk differences in the number of cases of suicidal thoughts or behaviors comparing drug versus placebo in pooled antidepressant trials. It shows changes per 1000 patients treated across age ranges: increases in patients under 25 and decreases in patients aged 25 and older.*

FDA Label Image

Table 3 (Table 3)

A data table titled 'Common Adverse Reactions in Pooled Placebo-Controlled Trials in Adults with MDD, OCD, PD, PTSD, SAD, and PMDD.' It compares the incidence percentages of various adverse reactions between sertraline hydrochloride (N=3066) and placebo (N=2293) groups. Categories include cardiac, eye, gastrointestinal, general disorders, metabolism, nervous system, psychiatric, reproductive, and skin disorders with detailed percentages of occurrences in each group.*

FDA Label Image

Table 4 (Table 4)

Data table showing the most common sexual adverse reactions (≥2% and twice placebo) in men or women from sertraline hydrochloride pooled controlled trials in adults with various conditions. The table compares incidence percentages for sertraline hydrochloride versus placebo in men (ejaculation failure, libido decreased, erectile dysfunction, ejaculation disorder, male sexual dysfunction) and women (libido decreased).*

FDA Label Image

Table 5 (Table 5)

A data table titled 'Clinically-Significant Drug Interactions with Sertraline Hydrochloride' detailing interactions by drug class, clinical impact, interventions, and examples. Categories include Monoamine Oxidase Inhibitors (MAOIs), Pimozide, other serotonergic drugs, antiplatelet agents, drugs highly bound to plasma protein, CYP2D6 substrates, phenytoin, and drugs that prolong the QTc interval.*

FDA Label Image

Treatment (Treat)

A text panel listing disorders including Major Depressive Disorder (MDD), Panic Disorder, Social Anxiety Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), and Premenstrual Dysphoric Disorder (PMDD).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.